To correct high blood pressure of the pulmonary artery, which can arise from congenital defects of the heart, an artificial heart ucan cost upwards of $190,000. Heart disease accounted for about one ...

Please provide your email address to receive an email when new articles are posted on . There is generally high awareness surrounding the 2022 guidelines for pulmonary hypertension, although some gaps ...

Referral to a PH expert centre, including for right heart catheterisation, confirms the diagnosis. Supportive measures include diuretic therapy for symptoms of right heart failure and fluid retention, ...

In treatment-naïve patients with PAH, initial monotherapy improves exercise capacity, hemodynamics, and outcomes when compared with those noted among untreated patients. In patients who are newly ...

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leading AI-driven health technology company and portfolio company of nference, announced a new study that revealed promising results in support of further ...

Please provide your email address to receive an email when new articles are posted on . At diagnosis, the area under the receiver operating characteristic curve in two test sets was 0.92 and 0.88.

Panelists discuss how the pathophysiology of pulmonary arterial hypertension involves complex mechanisms across multiple genetic and treatment pathways, with over 20 identified genes and four major ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Dr. Sathish Kumar Krishnan has spent years tackling a silent crisis in healthcare: pulmonary hypertension (PH), a condition that affects thousands but remains underdiagnosed and under-treated. As a ...